New Mexico 2025 Regular Session

New Mexico House Bill HM58 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	underscored material = new
2	2	[bracketed material] = delete
3	3	1
4	4	2
5	5	3
6	6	4
7	7	5
8	8	6
9	9	7
10	10	8
11	11	9
12	12	10
13	13	11
14	14	12
15	15	13
16	16	14
17	17	15
18	18	16
19	19	17
20	20	18
21	21	19
22	22	20
23	23	21
24	24	22
25	25	23
26	26	24
27	27	25
28	28	HOUSE MEMORIAL 58
29	29	57TH LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2025
30	30	INTRODUCED BY
31	31	Dayan Hochman-Vigil
32	32	A MEMORIAL
33	33	REQUESTING THE DEPARTMENT OF HEALTH TO STUDY PSILOCYBIN-BASED
34	34	MEDICATION TREATMENT.
35	35	WHEREAS, psilocybin, a naturally occurring psychedelic
36	36	compound found in certain mushrooms, has gained recognition for
37	37	its potential therapeutic applications, including treatment for
38	38	mental health conditions such as depression, anxiety and
39	39	posttraumatic stress disorder; and
40	40	WHEREAS, the use of psilocybin-based treatments has become
41	41	a topic of increasing interest in the medical and scientific
42	42	communities, with several jurisdictions across the United
43	43	States and globally exploring regulatory frameworks for the use
44	44	of psilocybin-based treatments in clinical settings; and
45	45	WHEREAS, New Mexico has recognized the importance of
46	46	advancing evidence-based health care solutions and ensuring the
47	47	.231353.2 underscored material = new
48	48	[bracketed material] = delete
49	49	1
50	50	2
51	51	3
52	52	4
53	53	5
54	54	6
55	55	7
56	56	8
57	57	9
58	58	10
59	59	11
60	60	12
61	61	13
62	62	14
63	63	15
64	64	16
65	65	17
66	66	18
67	67	19
68	68	20
69	69	21
70	70	22
71	71	23
72	72	24
73	73	25
74	74	safety, efficacy and accessibility of new treatment modalities
75	75	for its residents; and
76	76	WHEREAS, the department of health plays a central role in
77	77	regulating health care practices and safeguarding public health
78	78	within the state; and
79	79	WHEREAS, New Mexico would benefit from standardized
80	80	guidelines that ensure appropriate training for medical
81	81	professionals and robust testing protocols for psilocybin-based
82	82	treatments;
83	83	NOW, THEREFORE, BE IT RESOLVED BY THE HOUSE OF
84	84	REPRESENTATIVES OF THE STATE OF NEW MEXICO that the department
85	85	of health be requested to study the following:
86	86	A. the standardization of training requirements and
87	87	modalities for the use of psilocybin-based medication treatment
88	88	by examining the current landscape of psilocybin-based
89	89	medication treatments;
90	90	B. the establishment of clear testing protocols to
91	91	ensure the consistency, accuracy and safety of psilocybin
92	92	products;
93	93	C. the methods for determining psilocybin content,
94	94	variability in potency and quality control measures that
95	95	protect both patients and providers;
96	96	D. the considerations of both initial and ongoing
97	97	training requirements, ensuring that the training modalities
98	98	support safe, effective and ethical use of psilocybin as a
99	99	.231353.2
100	100	- 2 - underscored material = new
101	101	[bracketed material] = delete
102	102	1
103	103	2
104	104	3
105	105	4
106	106	5
107	107	6
108	108	7
109	109	8
110	110	9
111	111	10
112	112	11
113	113	12
114	114	13
115	115	14
116	116	15
117	117	16
118	118	17
119	119	18
120	120	19
121	121	20
122	122	21
123	123	22
124	124	23
125	125	24
126	126	25
127	127	therapeutic treatment;
128	128	E. the review of existing legal and regulatory
129	129	barriers to psilocybin-based medication treatment, including
130	130	state and federal restrictions, and recommendations for policy
131	131	adjustments that may facilitate safe and controlled access;
132	132	F. the examination of potential frameworks for
133	133	licensing, administration and oversight, including whether
134	134	psilocybin-based treatment should be limited to medical
135	135	professionals, offered in supervised clinical settings or made
136	136	available through licensed facilitators;
137	137	G. the evaluation of public health and safety
138	138	concerns, including considerations for proper screening of
139	139	patients, contraindications and integration with existing
140	140	mental health care services;
141	141	H. the assessment of economic and social equity
142	142	impacts, including strategies to ensure affordable and
143	143	equitable access to psilocybin-based treatments for underserved
144	144	populations, as well as opportunities for community
145	145	participation in the development of a regulatory framework;
146	146	I. the engagement of medical and scientific
147	147	experts, including representatives from universities, research
148	148	institutions and clinical trial programs, to provide guidance
149	149	on evidence-based best practices and safety standards;
150	150	J. the solicitation of input from stakeholders,
151	151	including health care professionals, indigenous and traditional
152	152	.231353.2
153	153	- 3 - underscored material = new
154	154	[bracketed material] = delete
155	155	1
156	156	2
157	157	3
158	158	4
159	159	5
160	160	6
161	161	7
162	162	8
163	163	9
164	164	10
165	165	11
166	166	12
167	167	13
168	168	14
169	169	15
170	170	16
171	171	17
172	172	18
173	173	19
174	174	20
175	175	21
176	176	22
177	177	23
178	178	24
179	179	25
180	180	medicine practitioners, mental health advocacy organizations
181	181	and members of the public, to inform policy recommendations;
182	182	K. the identification of potential funding sources
183	183	for future research and implementation efforts, including
184	184	federal grants, private research partnerships and state
185	185	appropriations; and
186	186	L. the establishment of a time line for
187	187	implementing any recommended regulatory or legislative changes
188	188	following the completion of the study, ensuring that findings
189	189	are used to inform future policymaking efforts; and
190	190	BE IT FURTHER RESOLVED that the department of health be
191	191	requested to submit a comprehensive report detailing the
192	192	department's findings, recommended policy changes and a
193	193	proposed framework for psilocybin-based medication treatment,
194	194	including potential pilot programs, licensing structures and
195	195	public health safeguards; and
196	196	BE IT FURTHER RESOLVED that a copy of this memorial be
197	197	transmitted to the secretary of health.
198	198	- 4 -
199	199	.231353.2